# Bollinger Innovations, Inc.: financial statements, quarterly

BINI · OTC · CIK 1499961 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/bini.md) · [Financials](/companies/bini/financials.md) · [Filings](/companies/bini/filings.md) · [Insiders](/companies/bini/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bini/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2022 (2022-09-30) | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0001437749-24-016668.md) | [0.3](/filings/0001437749-24-026065.md) | [0.1 d](/filings/0001437749-25-001816.md) | [0.0](/filings/0001437749-25-004413.md) | [0.0](/filings/0001437749-25-017812.md) | [0.1](/filings/0001437749-25-027081.md) | [1.0 d](/filings/0001437749-25-001816.md) | [2.9](/filings/0001437749-25-004413.md) | [5.0](/filings/0001437749-25-017812.md) | [0.5](/filings/0001437749-25-027081.md) |
| Cost of revenue | $m | not reported | not reported | [0.0](/filings/0001437749-24-016668.md) | [0.2](/filings/0001437749-24-026065.md) | [0.0 d](/filings/0001437749-25-001816.md) | not reported | [0.0](/filings/0001437749-25-017812.md) | [0.0](/filings/0001437749-25-027081.md) | [16.8 d](/filings/0001437749-25-001816.md) | [6.6](/filings/0001437749-25-004413.md) | [7.0](/filings/0001437749-25-017812.md) | [10.6](/filings/0001437749-25-027081.md) |
| Gross profit | $m | not reported | not reported | [0.0](/filings/0001437749-24-016668.md) | [0.1](/filings/0001437749-24-026065.md) | [0.0 d](/filings/0001437749-25-001816.md) | not reported | [0.0](/filings/0001437749-25-017812.md) | [0.0](/filings/0001437749-25-027081.md) | [(15.8) d](/filings/0001437749-25-001816.md) | [(3.7)](/filings/0001437749-25-004413.md) | [(2.0)](/filings/0001437749-25-017812.md) | [(10.1)](/filings/0001437749-25-027081.md) |
| Research and development | $m | [12.0 d](/filings/0001558370-24-000312.md) | [8.6](/filings/0001558370-24-001064.md) | [20.5](/filings/0001437749-24-016668.md) | [22.1](/filings/0001437749-24-026065.md) | [26.2 d](/filings/0001437749-25-001816.md) | [16.2](/filings/0001437749-25-004413.md) | [24.0](/filings/0001437749-25-017812.md) | [14.3](/filings/0001437749-25-027081.md) | [20.4 d](/filings/0001437749-25-001816.md) | [11.3](/filings/0001437749-25-004413.md) | [10.4](/filings/0001437749-25-017812.md) | [11.6](/filings/0001437749-25-027081.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(34.3) d](/filings/0001558370-24-000312.md) | [(73.6)](/filings/0001558370-24-001064.md) | [(67.9)](/filings/0001437749-24-016668.md) | [(53.8)](/filings/0001437749-24-026065.md) | [(182) d](/filings/0001437749-25-001816.md) | [(59.4)](/filings/0001437749-25-004413.md) | [(177)](/filings/0001437749-25-017812.md) | [(61.8)](/filings/0001437749-25-027081.md) | [(93.3) d](/filings/0001437749-25-001816.md) | [(51.4)](/filings/0001437749-25-004413.md) | [(65.8)](/filings/0001437749-25-017812.md) | [(58.2)](/filings/0001437749-25-027081.md) |
| Interest expense | $m | not reported | not reported | [1.9](/filings/0001437749-24-016668.md) | not reported | not reported | [0.3](/filings/0001437749-25-004413.md) | [0.3](/filings/0001437749-24-016668.md) | [8.3](/filings/0001437749-25-027081.md) | [40.6 d](/filings/0001437749-25-001816.md) | [18.7](/filings/0001437749-25-004413.md) | [7.5](/filings/0001437749-25-017812.md) | [25.7](/filings/0001437749-25-027081.md) |
| Income tax | $m | not reported | not reported | [(0.5)](/filings/0001437749-24-016668.md) | [0.5](/filings/0001437749-24-026065.md) | [(10.5) d](/filings/0001437749-25-001816.md) | [(1.7)](/filings/0001437749-25-004413.md) | [(2.2)](/filings/0001437749-25-017812.md) | [0.0](/filings/0001437749-25-027081.md) | [0.0 d](/filings/0001437749-25-001816.md) | [0.0](/filings/0001437749-25-004413.md) | [0.0](/filings/0001437749-25-017812.md) | [0.0](/filings/0001437749-25-027081.md) |
| Net income | $m | [(254) d](/filings/0001558370-24-000312.md) | [(376)](/filings/0001558370-24-001064.md) | [(115)](/filings/0001437749-24-016668.md) | [(309)](/filings/0001437749-24-026065.md) | [(172) d](/filings/0001437749-25-001816.md) | [(61.4)](/filings/0001437749-25-004413.md) | [(132)](/filings/0001437749-25-017812.md) | [(87.4)](/filings/0001437749-25-027081.md) | [(176) d](/filings/0001437749-25-001816.md) | [(115)](/filings/0001437749-25-004413.md) | [(47.1)](/filings/0001437749-25-017812.md) | [(130)](/filings/0001437749-25-027081.md) |
| Diluted EPS | $ per share | not reported | [(6233.08)](/filings/0001558370-24-001064.md) | [(1.30)](/filings/0001558370-23-009879.md) | [(1114.23)](/filings/0001437749-24-026065.md) | not reported | [(15.32)](/filings/0001558370-24-001064.md) | not reported | [(7.91)](/filings/0001437749-24-026065.md) | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | [(6233.08)](/filings/0001558370-24-001064.md) | [(1167.18)](/filings/0001437749-24-016668.md) | [(1114.23)](/filings/0001437749-24-026065.md) | not reported | [(91940.42)](/filings/0001437749-25-004413.md) | [(12041273.00)](/filings/0001437749-25-017812.md) | [(95987912.00)](/filings/0001437749-25-027081.md) | not reported | [(661.33)](/filings/0001437749-25-004413.md) | [(489.24)](/filings/0001437749-25-017812.md) | [(11231.39)](/filings/0001437749-25-027081.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2022 (2022-09-30) | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [54.1](/filings/0001558370-24-000312.md) | [68.1](/filings/0001558370-23-001277.md) | [60.3](/filings/0001558370-23-009879.md) | [214](/filings/0001558370-23-014900.md) | [155](/filings/0001437749-25-001816.md) | [81.5](/filings/0001558370-24-001064.md) | [22.4](/filings/0001437749-24-016668.md) | [3.5](/filings/0001437749-24-026065.md) | [10.3](/filings/0001437749-25-027081.md) | [2.3](/filings/0001437749-25-004413.md) | [1.4](/filings/0001437749-25-017812.md) | [0.5](/filings/0001437749-25-027081.md) |
| Current assets | $m | [86.3](/filings/0001558370-24-000312.md) | [136](/filings/0001558370-23-001277.md) | [98.9](/filings/0001558370-23-009879.md) | [255](/filings/0001558370-23-014900.md) | [198](/filings/0001437749-25-001816.md) | [144](/filings/0001558370-24-001064.md) | [88.9](/filings/0001437749-24-016668.md) | [67.6](/filings/0001437749-24-026065.md) | [63.2](/filings/0001437749-25-027081.md) | [59.9](/filings/0001437749-25-004413.md) | [52.9](/filings/0001437749-25-017812.md) | [42.4](/filings/0001437749-25-027081.md) |
| Total assets | $m | [303](/filings/0001558370-24-000312.md) | [441](/filings/0001558370-23-001277.md) | [403](/filings/0001437749-24-016668.md) | [560](/filings/0001437749-24-026065.md) | [422](/filings/0001437749-25-001816.md) | [381](/filings/0001437749-25-004413.md) | [214](/filings/0001437749-25-017812.md) | [192](/filings/0001437749-25-027081.md) | [179](/filings/0001437749-25-027081.md) | [173](/filings/0001437749-25-004413.md) | [150](/filings/0001437749-25-017812.md) | [89.2](/filings/0001437749-25-027081.md) |
| Current liabilities | $m | [122](/filings/0001558370-24-000312.md) | [397](/filings/0001558370-23-001277.md) | [121](/filings/0001558370-23-009879.md) | [190](/filings/0001558370-23-014900.md) | [140](/filings/0001437749-25-001816.md) | [96.4](/filings/0001558370-24-001064.md) | [83.5](/filings/0001437749-24-016668.md) | [127](/filings/0001437749-24-026065.md) | [183](/filings/0001437749-25-027081.md) | [246](/filings/0001437749-25-004413.md) | [209](/filings/0001437749-25-017812.md) | [186](/filings/0001437749-25-027081.md) |
| Total liabilities | $m | [146](/filings/0001558370-24-000312.md) | [420](/filings/0001558370-23-001277.md) | [140](/filings/0001558370-23-009879.md) | [208](/filings/0001558370-23-014900.md) | [149](/filings/0001437749-25-001816.md) | [109](/filings/0001558370-24-001064.md) | [96.7](/filings/0001437749-24-016668.md) | [139](/filings/0001437749-24-026065.md) | [195](/filings/0001437749-25-027081.md) | [267](/filings/0001437749-25-004413.md) | [220](/filings/0001437749-25-017812.md) | [196](/filings/0001437749-25-027081.md) |
| Long-term debt | $m | [5.2](/filings/0001558370-24-000312.md) | [4.9](/filings/0001558370-23-001277.md) | [7.6](/filings/0001558370-23-009879.md) | [7.3](/filings/0001558370-23-014900.md) | [0.0](/filings/0001437749-25-001816.md) | [7.6](/filings/0001558370-24-001064.md) | [0.0](/filings/0001437749-24-016668.md) | [0.0](/filings/0001437749-24-026065.md) | [0.0](/filings/0001437749-25-001816.md) | [13.2](/filings/0001437749-25-004413.md) | not reported | not reported |
| Current portion of debt | $m | [3.9](/filings/0001558370-24-000312.md) | [93.8](/filings/0001558370-23-001277.md) | [7.6](/filings/0001558370-23-009879.md) | [7.3](/filings/0001558370-23-014900.md) | [7.5](/filings/0001437749-25-001816.md) | [7.6](/filings/0001558370-24-001064.md) | [2.7](/filings/0001437749-24-016668.md) | [2.7](/filings/0001437749-24-026065.md) | [5.4](/filings/0001437749-25-001816.md) | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [58.7](/filings/0001558370-24-000312.md) | [20.7](/filings/0001437749-24-016668.md) | [263](/filings/0001437749-24-026065.md) | [352](/filings/0001437749-24-026065.md) | [209](/filings/0001437749-25-001816.md) | [211](/filings/0001558370-24-001064.md) | [95.1](/filings/0001437749-24-016668.md) | [34.9](/filings/0001437749-24-026065.md) | [(28.6)](/filings/0001437749-25-027081.md) | [(103)](/filings/0001437749-25-004413.md) | [(73.0)](/filings/0001437749-25-017812.md) | [(108)](/filings/0001437749-25-027081.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q4 FY2022 (2022-09-30) | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(22.6) d](/filings/0001558370-24-000312.md) | [(33.2)](/filings/0001558370-24-001064.md) | [(34.3) d](/filings/0001437749-24-016668.md) | [(46.1) d](/filings/0001558370-23-014900.md) | [(65.5) d](/filings/0001437749-25-001816.md) | [(59.9)](/filings/0001437749-25-004413.md) | [(48.6) d](/filings/0001437749-25-017812.md) | [(36.7) d](/filings/0001437749-25-027081.md) | [(40.4) d](/filings/0001437749-25-001816.md) | [(25.6)](/filings/0001437749-25-004413.md) | [(23.0) d](/filings/0001437749-25-017812.md) | [(20.8) d](/filings/0001437749-25-027081.md) |
| Capital expenditure | $m | [0.6 d](/filings/0001558370-24-000312.md) | [0.7](/filings/0001558370-24-001064.md) | [3.6 d](/filings/0001437749-24-016668.md) | [10.0 d](/filings/0001558370-23-014900.md) | [0.2 d](/filings/0001437749-25-001816.md) | [6.9](/filings/0001437749-25-004413.md) | [5.6 d](/filings/0001437749-25-017812.md) | [1.6 d](/filings/0001437749-25-027081.md) | [0.7 d](/filings/0001437749-25-001816.md) | [2.2](/filings/0001437749-25-004413.md) | [1.6 d](/filings/0001437749-25-017812.md) | [0.4 d](/filings/0001437749-25-027081.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q4 FY2020 (2020-12-31) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q1 FY2022 (2021-12-31) | Q2 FY2022 (2022-03-31) | Q3 FY2022 (2022-06-30) | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q3 FY2024 (2024-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [5.1](/filings/0001558370-22-001130.md) | [5.1](/filings/0001558370-22-009134.md) | [5.3](/filings/0001558370-22-013480.md) | [17.5](/filings/0001558370-23-001277.md) | [2.1](/filings/0001558370-23-009879.md) | [1.7](/filings/0001558370-23-014900.md) | [0.1](/filings/0001558370-24-001064.md) | [82.4](/filings/0001558370-23-009879.md) | [0.3](/filings/0001437749-24-026065.md) | [4.0](/filings/0001558370-24-001064.md) | [12.1](/filings/0001437749-24-026065.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,604,935 at 2025-08-11, from the cover of the [10-Q/A filed 2025-08-15](/filings/0001437749-25-027081.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.